Gary S. Gillheeney - May 13, 2022 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Signature
/s/ William R. Kolb, Attorney-in-Fact
Stock symbol
ORGO
Transactions as of
May 13, 2022
Transactions value $
-$1,583,869
Form type
4
Date filed
5/17/2022, 08:11 PM
Previous filing
Apr 5, 2022
Next filing
May 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Options Exercise $14.7K +14.8K +3.72% $0.99 413K May 13, 2022 Direct
transaction ORGO Class A Common Stock Options Exercise $120K +122K +29.43% $0.99 535K May 13, 2022 Direct
transaction ORGO Class A Common Stock Sale -$89.7K -14.8K -2.77% $6.06 520K May 13, 2022 Direct F1, F2
transaction ORGO Class A Common Stock Sale -$751K -122K -23.39% $6.18 398K May 13, 2022 Direct F1, F3
transaction ORGO Class A Common Stock Options Exercise $79.6K +80.4K +20.18% $0.99 479K May 16, 2022 Direct
transaction ORGO Class A Common Stock Sale -$476K -80.4K -16.79% $5.92 398K May 16, 2022 Direct F1, F4
transaction ORGO Class A Common Stock Options Exercise $97.1K +98.1K +24.63% $0.99 496K May 17, 2022 Direct
transaction ORGO Class A Common Stock Sale -$579K -98.1K -19.76% $5.90 398K May 17, 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -14.8K -2.85% $0.00 505K May 13, 2022 Class A Common Stock 14.8K $0.99 Direct F6
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -122K -7.42% $0.00 1.52M May 13, 2022 Class A Common Stock 122K $0.99 Direct F6
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -80.4K -5.3% $0.00 1.44M May 16, 2022 Class A Common Stock 80.4K $0.99 Direct F6
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -98.1K -6.83% $0.00 1.34M May 17, 2022 Class A Common Stock 98.1K $0.99 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.16, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.06 to $6.32, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $6.13, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.83 to $6.06, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
F6 100% of the shares subject to the option are fully vested and exercisable.